REGN vs TECH — Key Metrics

Metric REGN (REGENERON PHARMACEUTICALS INC) TECH (BIO-TECHNE CORP)
Price945.5372.75
Market Cap97.81 Billion11.43 Billion
P/E (TTM)20.1166.14
P/B (Quarterly)2.8655.284
P/S (TTM)5.799.3
Net Profit Margin (TTM)28.514.0
Gross Margin (TTM)85.865.8
ROE (TTM)15.18.2
Revenue Growth YoY (TTM)n/an/a

Upfront Investment - S&P 500 Stock Comparison & AI Analysis

AI-powered analysis and comparison tools for S&P 500 stocks, helping investors make data-driven decisions with delayed market data and portfolio modeling.

REGENERON PHARMACEUTICALS INC
vs
 
BIO-TECHNE CORP
 
REGENERON PHARMACEUTICALS INC
vs
 
BIO-TECHNE CORP
Performance Comparison
AI Model Recommendation
REGN · REGENERON PHARMACEUTICALS INC

Outperform

60
UnderperformOutperform
TECH · BIO-TECHNE CORP

Underperform

-43
UnderperformOutperform
Recommendation Summary

Stock REGN is projected to outperform the market, stock TECH is projected to underperform the market. Upfront Recommendation: REGN.

Financial Metrics
Prices delayed ~15 min
REGN Metrics TECH
$945.53 Price $72.75
— Market Capitalization —
20.11 Price to Earnings Ratio 66.14
5.79 Price to Sales 9.3
25.56 Price to FCF Ratio 37.08
6.75 Price to Gross Profit 14.15
14.83 Price to R&D 117.98
4.7 Price to Current Assets 13.86

REGN vs TECH at a glance

Regeneron Pharmaceuticals INC (REGN) and Bio-techne Corp (TECH) are both Biotechnology companies in the Healthcare sector. REGN is the larger, at $97.8 billion in market value against $11.4 billion for TECH, about 8.6 times the size.

On trailing-twelve-month figures, REGN trades at 20.1 times trailing earnings and TECH at 66.1; net profit margins are 28.5% and 14.0%.

The Upfront Investment model currently rates REGN Outperform and TECH Underperform as of November 18, 2026. The rating ranks the model's medium-term return forecast against the other stocks it scores; it is a statistical forecast, not investment advice.